PURPOSE: To quantify vitreous @entity535 concentrations in pressure-induced @entity2479 and to evaluate the neuroprotective effect of @entity3393 , a @entity1024 ( @entity143 ) antagonist, administered before and at two time intervals after @entity63 . METHODS: @entity2479 was induced in 10 @entity35 by elevating the intraocular pressure to 120 mm Hg. The concentrations of the @entity1522 of vitreous samples were measured by high-pressure liquid chromatography. In another series of 56 @entity35 , @entity63 was induced in a similar fashion. Fifteen @entity35 received 20 mg/kg x day @entity3393 by a subcutaneous osmotic pump starting 2 days before @entity63 , 13 @entity35 received 10 mg/kg @entity3393 intraperitoneally (ip) 0.5 and 4.5 hours after reperfusion, 13 @entity35 received 10 mg/kg @entity3393 ip 3.5 and 7.5 hours after reperfusion, and 15 @entity35 received the vehicle alone. @entity2806 was histologically quantified 14 days after @entity63 . RESULTS: Compared with the nonischemic fellow eyes, there was an elevation (P < 0.05) in the mean vitreous concentration of @entity2227 (223%+/-41%) and @entity2228 (428%+/-92%). The percentage of surviving neurons in the @entity4494 cell layer was 33%+/-3% in the controls, 61%+/-5% (P < 0.001) when @entity3393 was infused subcutaneously before @entity63 , 52%+/-5% (P < 0.05) when @entity3393 was injected ip 0.5 and 4.5 hours after @entity63 , and 48%+/-5% (P > 0.05) when injected ip 3.5 and 7.5 hours after @entity63 . CONCLUSIONS: @entity2479 increased vitreous concentrations of @entity2227 and @entity2228 . Both @entity1522 were agonists at the @entity143 receptor. The @entity143 receptor antagonist @entity3393 reduced @entity4494 cell loss when given systemically before or within 30 minutes of @entity2479 .

XXXX is neuroprotective in a @entity35 model of pressure-induced @entity2479 .

@entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids'] @entity1024 :: ('CHEBI:31882', 'Chemical') :: ['N-methyl-D-aspartate'] @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate'] @entity2806 :: ('MESH:D002545', 'Disease') :: ['Ischemic damage'] @entity2479 :: ('MESH:D012173', 'Disease') :: ['retinal ischemia', 'Retinal ischemia'] @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia'] @entity2228 :: ('CHEBI:57305', 'Chemical') :: ['glycine'] @entity3393 :: ('MESH:D008559', 'Chemical') :: ['memantine'] @entity4494 :: ('MESH:D045888', 'Disease') :: ['ganglion'] @entity143 :: ('CHEBI:6121', 'Chemical') :: ['NMDA'] @entity35 :: ('10116', 'Species') :: ['rats']
@entity3393 :: (MESH:D008559,Chemical) :: ['Memantine']
